FDA Enhertu Approval: Market Calls It Done

The FDA approval market for Enhertu has stopped being a question. At 98.1% YES, traders have effectively closed the debate two days before the May 18 resolution date. The contract opened at 50 cents and now trades at 98 cents. That 48-cent move tells you everything about how new information landed on this market over the past few weeks.

Enhertu is a HER2-directed antibody-drug conjugate developed jointly by Daiichi Sankyo and AstraZeneca. The drug already holds FDA approval for HER2-positive and HER2-low breast cancer, HER2-mutant non-small cell lung cancer, and HER2-positive gastric cancer. This contract almost certainly tracks a new indication or an expanded label decision that was scheduled to move through the FDA review calendar by May 18, 2026.

How the Enhertu FDA Contract Resolves

YES pays if the FDA grants the relevant Enhertu approval on or before May 18, 2026. NO pays if the agency declines, issues a complete response letter, or lets the PDUFA date pass without a decision. The FDA’s Center for Drug Evaluation and Research makes the call. Resolution follows the official FDA action, not press releases or leaks.

• YES: $0.98 per share, 98.1% implied probability. The FDA issues approval by May 18.
• NO: $0.02 per share, 1.9% implied probability. The FDA delays or rejects.

A NO outcome requires the FDA to miss the PDUFA date, issue a complete response letter, or request additional safety data. Complete response letters are rare when a drug has an established safety profile across multiple prior approvals. The FDA declined Enhertu contracts on this market would pay only if a regulatory surprise interrupts a review that has so far moved smoothly toward its deadline.

Sponsored Partner

A Surge in Conviction, Not Just Price

The 1-hour and 24-hour price change both register at plus 18.3%, with a trend score of 68.67. Those three numbers point to a single catalyst: something confirmed in the last 24 hours that removed the remaining uncertainty traders were pricing before today. That could be an FDA communication, a Daiichi Sankyo or AstraZeneca press release, or a market participant with visible access to PDUFA-adjacent information moving size into YES.

Total market volume sits at $1,831, with $969 trading in the last 24 hours. Liquidity is $1,152. These are thin numbers. Volume below $1 million means a relatively small order can move this market sharply. The 18.3% single-session jump is consistent with thin liquidity, not necessarily a massive information edge. That said, 98.1% on a binary regulatory outcome two days from resolution is a strong consensus reading even in a small market.

• 1-hour change: Plus 18.3%, combined with the 24-hour figure and trend score of 68.67, this is a single conviction signal, not three separate data points.
• Total volume: $1,831 total, $969 in the last 24 hours. Thin liquidity means new data can move price sharply in either direction before May 18.
• Open interest: Zero, which means most positions are already settled or the contract structure does not track this metric. Resolution is the next meaningful event.
• Related markets: The Daraxonrasib approval market sits at 71%, while Truqap and Camizestrant both price near zero. The Enhertu market at 98.1% is well above the rest of the AstraZeneca pipeline cluster.

Lines Analysis: What the Data Says About Enhertu

Enhertu’s existing approval history is the strongest signal in this market. The FDA has approved this drug across four distinct indications. Each prior approval added safety and efficacy data to a file the FDA now knows well. Drugs with multiple prior approvals face a lower informational bar on subsequent applications. The agency’s review team is not encountering Enhertu for the first time. The PDUFA framework gives the FDA a hard deadline, and the 98.1% price suggests the market believes that deadline arrives with an approval attached.

The scenario where NO becomes real is narrow but real. An unexpected safety signal from post-market surveillance could trigger a clinical hold or a complete response letter. A manufacturing inspection failure at a Daiichi Sankyo facility could delay the approval past May 18. These are low-probability events on a drug with this track record, but they are the specific mechanisms that would flip this contract. The market prices that combined risk at under 2%.

• FDA PDUFA date for May 18: Any confirmation or communication from the FDA before the deadline would move YES toward 100.
• Daiichi Sankyo or AstraZeneca press release: An approval announcement before market close on May 18 resolves this contract immediately.
• Complete response letter: Issuance of a CRL would collapse YES to near zero within minutes of the announcement.
• Manufacturing inspection outcome: A facility flag from the FDA’s Office of Pharmaceutical Quality is the most plausible non-safety path to a NO outcome.

At $1,831 in total volume, this is not a high-liquidity market. The 98.1% reading reflects genuine trader conviction, but the thin book means a single informed participant moved the price significantly in the last 24 hours. The data favors YES. The only honest question is whether a tail-risk regulatory event materializes before May 18.

LINES VERDICT

Approval Expected: Market Treats This as Settled

The data doesn’t care about the politics, and here the data is clear: a drug with four prior FDA approvals, a confirmed PDUFA date, and a 98.1% market consensus is about as close to a settled outcome as prediction markets produce.

What the market says: 98.1% YES means traders have priced this as an approval. With resolution on May 18, 2026 and only 48 hours remaining, the window for new information is narrow. Thin liquidity means any surprise moves fast.

Key unknown: The single event that would reprice this contract is an FDA complete response letter or an unexpected manufacturing hold issued before the May 18 deadline. Nothing else in the current data environment points toward that outcome.

Scientific and Regulatory Context

Enhertu’s clinical profile spans multiple tumor types that express HER2. The drug’s mechanism, trastuzumab deruxtecan, delivers a topoisomerase I inhibitor directly to HER2-expressing cancer cells. The FDA granted Enhertu Breakthrough Therapy designation and accelerated approval pathways on prior applications, which signals a constructive regulatory relationship between the agency and the sponsors. That history matters when the FDA’s review team evaluates an additional indication. Established drugs with positive safety databases move through the approval process differently than first-time applications. The market price at 98.1% reflects that institutional knowledge, priced two days before resolution.

Frequently Asked Questions

• What does 98.1% mean in this market? It means traders collectively assign a 98.1% chance the FDA approves the relevant Enhertu application by May 18, 2026. Probabilities shift as new regulatory information emerges, even this close to the deadline.
• What does the NO contract pay out on? NO resolves at $1.00 per share if the FDA issues a complete response letter, delays past the PDUFA date, or takes no action by May 18, 2026. NO currently trades at $0.02, implying a 1.9% chance of that outcome.
• What single event would move the price most before resolution? An official FDA complete response letter or an Enhertu approval press release from Daiichi Sankyo or AstraZeneca would reprice this contract immediately and decisively.
• When does this contract resolve? The resolution date is May 18, 2026. The FDA’s official action, not media reports, triggers resolution.
• Is $1,831 in volume enough to trust the price? Thin volume means fewer traders set the price. The 98.1% reading is consistent with Enhertu’s regulatory history, but low liquidity means a single large trade could shift the price before resolution. Treat it as directionally accurate, not structurally deep.

This analysis reflects market conditions as of 2026-05-16 00:19:57. Prediction market probabilities are volatile and shift as new data and regulatory decisions emerge, especially as the 2026-05-18 00:00:00 resolution date approaches. Lines.com does not accept bets or provide financial or gambling advice. All market outcomes are uncertain.